196 related articles for article (PubMed ID: 10353523)
1. Treatment of infection due to Mycobacterium avium complex.
Powderly WG
Pediatr Infect Dis J; 1999 May; 18(5):468-9. PubMed ID: 10353523
[No Abstract] [Full Text] [Related]
2. Criteria for use of rifabutin in adult patients with human immunodeficiency virus (HIV)-associated disease.
Fish N; Kass CL
Am J Health Syst Pharm; 1996 Jul; 53(13):1598-9. PubMed ID: 8809283
[No Abstract] [Full Text] [Related]
3. Rifabutin levels may increase with fluconazole during MAC treatment.
AIDS Patient Care STDS; 1996 Oct; 10(5):310. PubMed ID: 11361528
[No Abstract] [Full Text] [Related]
4. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team.
Benson CA; Williams PL; Cohn DL; Becker S; Hojczyk P; Nevin T; Korvick JA; Heifets L; Child CC; Lederman MM; Reichman RC; Powderly WG; Notario GF; Wynne BA; Hafner R
J Infect Dis; 2000 Apr; 181(4):1289-97. PubMed ID: 10762562
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic antibiotic receives speedy FDA approval to reduce MAC disease in advanced HIV.
AIDS Patient Care STDS; 1996 Dec; 10(6):379. PubMed ID: 11361569
[No Abstract] [Full Text] [Related]
6. Uveitis during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol.
Lowe SH; Kroon FP; Bollemeyer JG; Stricker BH; van 't Wout JW
Neth J Med; 1996 Jun; 48(6):211-5. PubMed ID: 8710040
[TBL] [Abstract][Full Text] [Related]
7. Treatment of disseminated Mycobacterium avium complex disease: a clinician's perspective.
Benson CA
Res Microbiol; 1996; 147(1-2):16-24. PubMed ID: 8761717
[No Abstract] [Full Text] [Related]
8. Prevention and treatment of Mycobacterium avium complex infection.
Mangura BT; Reichman LB
Res Microbiol; 1994; 145(3):181-7. PubMed ID: 7809470
[No Abstract] [Full Text] [Related]
9. Risk-benefit assessment of therapies for Mycobacterium avium complex infections.
Griffith DE
Drug Saf; 1999 Aug; 21(2):137-52. PubMed ID: 10456381
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group.
Havlir DV; Dubé MP; Sattler FR; Forthal DN; Kemper CA; Dunne MW; Parenti DM; Lavelle JP; White AC; Witt MD; Bozzette SA; McCutchan JA
N Engl J Med; 1996 Aug; 335(6):392-8. PubMed ID: 8676932
[TBL] [Abstract][Full Text] [Related]
11. Advances in the diagnosis and treatment of Mycobacterium avium complex (MAC) disease.
Benson C
AIDS Patient Care; 1994 Jun; 8(3):138-40. PubMed ID: 11362136
[No Abstract] [Full Text] [Related]
12. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS.
Cohn DL; Fisher EJ; Peng GT; Hodges JS; Chesnut J; Child CC; Franchino B; Gibert CL; El-Sadr W; Hafner R; Korvick J; Ropka M; Heifets L; Clotfelter J; Munroe D; Horsburgh CR
Clin Infect Dis; 1999 Jul; 29(1):125-33. PubMed ID: 10433575
[TBL] [Abstract][Full Text] [Related]
13. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.
Shafran SD; Singer J; Zarowny DP; Phillips P; Salit I; Walmsley SL; Fong IW; Gill MJ; Rachlis AR; Lalonde RG; Fanning MM; Tsoukas CM
N Engl J Med; 1996 Aug; 335(6):377-83. PubMed ID: 8676931
[TBL] [Abstract][Full Text] [Related]
14. Current strategies for the prevention and treatment of disseminated Mycobacterium avium complex infection in patients with AIDS.
Wright J
Pharmacotherapy; 1998; 18(4):738-47. PubMed ID: 9692648
[TBL] [Abstract][Full Text] [Related]
15. Withdrawal of Mycobacterium avium complex suppressive therapy in HIV-1-infected patients on highly active antiretroviral therapy.
Martínez E; Miró JM; González J; Mallolas J; Gatell JM
AIDS; 1999 Jan; 13(1):147-8. PubMed ID: 10207565
[No Abstract] [Full Text] [Related]
16. Prevention strategies for Mycobacterium avium-intracellulare complex (MAC) infection. A review of recent studies in patients with AIDS.
Cohn DL
Drugs; 1997; 54 Suppl 2():8-15; discussion 28-9. PubMed ID: 9358195
[TBL] [Abstract][Full Text] [Related]
17. Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients.
Dautzenberg B; Castellani P; Pellegrin JL; Vittecoq D; Truffot-Pernot C; Pirotta N; Sassella D
Antimicrob Agents Chemother; 1996 Jul; 40(7):1722-5. PubMed ID: 8807071
[TBL] [Abstract][Full Text] [Related]
18. Quantitative cultures and drug susceptibility testing of Mycobacterium avium clinical isolates before and during the antimicrobial therapy.
Heifets LB
Res Microbiol; 1994; 145(3):188-96. PubMed ID: 7809471
[No Abstract] [Full Text] [Related]
19. Managing HIV. Part 5: Treating secondary outcomes. 5.15 HIV and non-tuberculous mycobacterial infection.
Hoy JF; Marriott D; Gottlieb T
Med J Aust; 1996 May; 164(9):543-5. PubMed ID: 8649292
[TBL] [Abstract][Full Text] [Related]
20. How to treat bacteraemic Mycobacterium avium complex disease.
Chin DP; Hopewell PC
Lancet; 1995 Oct; 346(8980):920-1. PubMed ID: 7564723
[No Abstract] [Full Text] [Related]
[Next] [New Search]
